Maxcyte (MXCT) Accumulated Expenses (2020 - 2026)

Maxcyte (MXCT) has reported Accumulated Expenses for 7 consecutive years, with $4.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Accumulated Expenses fell 34.81% year-over-year to $4.2 million in Q2 2026; TTM through Jun 2026 was $4.2 million, a 34.81% decrease from a year earlier, with the FY2025 full-year figure at $7.8 million, down 5.9% from the prior year.
• Accumulated Expenses was $4.2 million for Q2 2026 at Maxcyte, down from $4.4 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $11.3 million in Q4 2023 and troughed at $3.9 million in Q1 2022.
• A 5-year average of $7.2 million and a median of $7.4 million in 2024 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses soared 78.59% in 2023 and sank 34.81% in 2026, its largest moves.
• Over 5 years, Accumulated Expenses stood at $8.3 million in 2022, then soared by 36.35% to $11.3 million in 2023, then dropped by 26.33% to $8.3 million in 2024, then declined by 5.9% to $7.8 million in 2025, then slumped by 46.62% to $4.2 million in 2026.
• The last three Accumulated Expenses figures came in at $4.2 million (Q2 2026), $4.4 million (Q1 2026), and $7.8 million (Q4 2025), per Business Quant data.